ELA026 demonstrated a high overall response rate (ORR) across a range of sHLH patients and a favorable safety profile in this life-threatening hyperinflammatory condition In patients with the poorest prognosis, those with malignancy-associated HLH, early treatment with ELA026 resulted in 100% ORR and improved survival SOUTH SAN FRANCISCO, CA, June 16, 2024 – Electra Therapeutics,...

Data from Phase 1b study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) to be presented on Sunday, June 16, 2024 SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical...

SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today the appointment of Graham Parry, PhD, as Chief Scientific Officer and Kim-Hien Dao, DO, PhD, as Chief Medical Officer. Both executives have deep...

ELA026 showed favorable safety and achieved overall response rate (ORR) of 70% in sHLH patients Majority of enrolled patients were in difficult-to-treat subtypes of sHLH associated with malignancies and relapsed/refractory disease SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases...

Company expands board of directors and appoints Matthew Fust as independent director Building on positive clinical results for its lead antibody candidate, Electra is positioned to expand therapeutic opportunities in immunological diseases and cancer SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets...

Company to reveal first clinical data from Phase 1b study of ELA026, its lead product candidate for life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 2, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, announced today that the company will present the initial...

Ongoing Phase 1b study progressing in US and EU for ELA026 in sHLH, a life-threatening inflammatory disease Preclinical data demonstrate ELA026 proof-of-mechanism of SIRP targeting and depletion of pathological immune cells that drive sHLH Company also presents results of sHLH natural history study SOUTH SAN FRANCISCO, CA, December 12, 2022 – Electra Therapeutics, Inc., a clinical...

Company’s lead product candidate, ELA026, is in a clinical study for a life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 3, 2022 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today that the company will present three posters related to...

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells Financing enables lead product candidate, ELA026, to reach clinical proof of concept in the inflammatory disease sHLH, expansion of ELA026 into other indications, and advancement of two additional programs towards the clinic SOUTH SAN FRANCISCO, CA, February 16,...